{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:19:36Z","timestamp":1771503576357,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006356","name":"University of Southern Denmark","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To ensure high-quality screening programmes and effective utilization of resources, it is important to monitor how cancer detection is affected by different strategies performed at recall assessment. This study aimed to describe procedures performed at recall assessment and compare and evaluate the performance of the assessment in Denmark, Norway, and Spain in terms of screen-detected cancer (SDC) and interval cancer (IC) rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included women aged 50\u201369\u00a0years from Denmark, Norway, and Spain, who were recalled for assessment after screening mammography, and recorded all procedures performed during six months after diagnosis, and the timing of the procedures. Women were followed for two years and screen-detected and interval cancer, and sensitivity of recall was calculated and compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, data from 24,645 Danish, 30,050 Norwegian, and 41,809 Spanish women were included in the study. Most of the women had some assessment within 2\u00a0months in all three countries. SDC rates were higher in Denmark (0.57) and Norway (0.60) compared to Spain (0.38), as were the IC rates, i.e. 0.25 and 0.18 vs. 0.12, respectively. The sensitivity of the diagnostic follow-up was somewhat higher in Denmark (98.3%) and Norway (98.2%), compared to Spain (95.4%), but when excluding non-invasive assessment pathways, the sensitivities were comparable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This comparison study showed variation in the assessment procedures used in the three countries as well as the SDC and IC rates and the sensitivity of recall.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-07219-0","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T05:02:00Z","timestamp":1706504520000},"page":"135-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain"],"prefix":"10.1007","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-0351","authenticated-orcid":false,"given":"Susanne Fogh","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silje","family":"Sagstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-3301","authenticated-orcid":false,"given":"Javier","family":"Louro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9076-8918","authenticated-orcid":false,"given":"Marta","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2528-0382","authenticated-orcid":false,"given":"Xavier","family":"Castells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-8939","authenticated-orcid":false,"given":"Solveig","family":"Hofvind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-4176","authenticated-orcid":false,"given":"Sisse","family":"Njor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"issue":"5","key":"7219_CR1","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3892\/ijo.2014.2632","volume":"45","author":"E Altobelli","year":"2014","unstructured":"Altobelli E, Lattanzi A (2014) Breast cancer in European Union: an update of screening programmes as of March 2014 (review). Int J Oncol 45(5):1785\u20131792","journal-title":"Int J Oncol"},{"key":"7219_CR2","unstructured":"Perry N, Broeders M, de Wolf C, T\u00f6rnberg S, Holland R, von Karsa L, et al. (2006) European guidelines for quality assurance in breast cancer screening and diagnosis. 4th edn, p 416"},{"issue":"8","key":"7219_CR3","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.10453","volume":"94","author":"IA Olivotto","year":"2002","unstructured":"Olivotto IA, Gomi A, Bancej C, Brisson J, Tonita J, Kan L et al (2002) Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. Cancer 94(8):2143\u20132150","journal-title":"Cancer"},{"key":"7219_CR4","doi-asserted-by":"crossref","unstructured":"Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, et al. (2018) Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA: A Cancer Journal for Clinicians","DOI":"10.3322\/caac.21452"},{"issue":"3","key":"7219_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1471-6712.2008.00634.x","volume":"23","author":"B Hafslund","year":"2009","unstructured":"Hafslund B, Nortvedt MW (2009) Mammography screening from the perspective of quality of life: a review of the literature. Scand J Caring Sci 23(3):539\u2013548","journal-title":"Scand J Caring Sci"},{"issue":"1","key":"7219_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12885-020-07289-z","volume":"20","author":"S Muratov","year":"2020","unstructured":"Muratov S, Canelo-Aybar C, Tarride J-E, Alonso-Coello P, Dimitrova N, Borisch B et al (2020) Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators. BMC Cancer 20(1):795","journal-title":"BMC Cancer"},{"key":"7219_CR7","unstructured":"Dansk Kvalitetsdatabase for Mammografiscreening (2007) Mammografiscreening i Danmark. Kliniske Retningslinjer [Mammography screening in Denmark. Clinical guidelines]. Contract No.: Report"},{"key":"7219_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/CLEP.S99467","volume":"8","author":"EM Mikkelsen","year":"2016","unstructured":"Mikkelsen EM, Njor SH, Vejborg I (2016) Danish quality database for mammography screening. Clin Epidemiol 8:661\u2013666","journal-title":"Clin Epidemiol"},{"key":"7219_CR9","unstructured":"Sundhedsstyrelsen (2018) Pakkeforl\u00f8b for brystkr\u00e6ft [breast cancer care pathway] (in Danish) Copenhagen [Available from: https:\/\/www.sst.dk\/da\/Viden\/Kraeft\/Kraeftpakkeforloeb\/Oversigt-over-kraeftpakkeforloeb"},{"key":"7219_CR10","unstructured":"Styregruppen for Dansk Kvalitetsdatase for Mammografiscreening (2019) Dansk Kvalitetsdatabase for Mammografiscreening. \u00c5rsrapport 2019 [Danish quality database of mammography screening, Report 2019]: Regionernes Kliniske Kvalitetsudviklingsprogram (RKKP); [Available from: https:\/\/www.sundhed.dk\/content\/cms\/78\/4678_dkms_rapport2019_endelig.pdf"},{"issue":"7","key":"7219_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10654-007-9137-y","volume":"22","author":"S Hofvind","year":"2007","unstructured":"Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P (2007) Using the European guidelines to evaluate the Norwegian breast cancer screening program. Eur J Epidemiol 22(7):447\u2013455","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"7219_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1148\/radiol.14131502","volume":"272","author":"S Hofvind","year":"2014","unstructured":"Hofvind S, Skaane P, Elmore JG, Sebu\u00f8deg\u00e5rd S, Hoff SR, Lee CI (2014) Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Radiology 272(1):52\u201362","journal-title":"Radiology"},{"key":"7219_CR13","volume-title":"Breast Screen Norway: 25 years of organized screening","author":"EWH\u00c5S Bj\u00f8rnson","year":"2022","unstructured":"Bj\u00f8rnson EWH\u00c5S, Sagstad S, Larsen M, Thy J, Mangerud G, Ertzaas AK, Hofvind S (2022) Breast Screen Norway: 25 years of organized screening. Cancer Registry of Norway, Oslo"},{"issue":"Suppl 3","key":"7219_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/annonc\/mdq085","volume":"21","author":"N Ascunce","year":"2010","unstructured":"Ascunce N, Salas D, Zubizarreta R, Almaz\u00e1n R, Ib\u00e1\u00f1ez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):43\u201351","journal-title":"Ann Oncol"},{"key":"7219_CR15","unstructured":"Sickles EDO CB, LW et al. (2013) ACR BI-RADS\u00ae mammography. In: ACR BI-RADS\u00ae Atlas, Breast imaging reporting and data system. American College of Radiology, Reston"},{"key":"7219_CR16","unstructured":"Red de Programas de Cribado de C\u00e1ncer. Programas de Cribado de C\u00e1ncer de Mama. Informe de evaluaci\u00f3n 2017. Available from: www.cribadocancer.es"},{"issue":"7","key":"7219_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39(7):42\u201345","journal-title":"Scand J Public Health"},{"issue":"7_suppl","key":"7219_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1403494810393563","volume":"39","author":"B Bjerregaard","year":"2011","unstructured":"Bjerregaard B, Larsen OB (2011) The Danish Pathology Register. Scand J Public Health. 39(7_suppl):72\u201374","journal-title":"Scand J Public Health."},{"key":"7219_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish national patient registry: a review of content, data quality, and research potential (Report). Clin Epidemiol 7:449","journal-title":"Clin Epidemiol"},{"issue":"8","key":"7219_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 29(8):541\u2013549","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"7219_CR21","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3390\/ijerph19052625","volume":"19","author":"M Rom\u00e1n","year":"2022","unstructured":"Rom\u00e1n M, Louro J, Posso M, Vidal C, Bargall\u00f3 X, V\u00e1zquez I et al (2022) Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography. Int J Environ Res Public Health 19(5):2625","journal-title":"Int J Environ Res Public Health"},{"key":"7219_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.breast.2020.09.005","volume":"54","author":"J Louro","year":"2020","unstructured":"Louro J, Rom\u00e1n M, Posso M, Comerma L, Vidal C, Saladi\u00e9 F et al (2020) Differences in breast cancer risk after benign breast disease by type of screening diagnosis. Breast 54:343\u2013348","journal-title":"Breast"},{"issue":"2","key":"7219_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JOP.2011.000413","volume":"8","author":"ML Quan","year":"2012","unstructured":"Quan ML, Shumak RS, Majpruz V, Holloway CMD, O\u2019Malley FP, Chiarelli AM (2012) Improving work-up of the abnormal mammogram through organized assessment: results from the Ontario breast screening program. J Oncol Pract 8(2):107\u2013112","journal-title":"J Oncol Pract"},{"key":"7219_CR24","unstructured":"Screening & Immunisations Team (NHS Digital) & PHE Screening PHE (2020) Breast screening programme England, 2018\u201319 [homepage on the internet]. [Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/breast-screening-programme\/england---2018-19"},{"key":"7219_CR25","unstructured":"Netherlands Comprehensive Cancer Organization (2018) National evaluation of breast cancer screening in the Netherlands June 2018 [homepage on the internet]. [updated May 2018. Available from: https:\/\/www.iknl.nl\/en\/screening"},{"key":"7219_CR26","unstructured":"Helsedirektoratet (2014) Brystkreft [updated 29\/04\/2021. Available from: https:\/\/www.helsedirektoratet.no\/nasjonale-forlop\/brystkreft"},{"issue":"1","key":"7219_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/096914130301100107","volume":"11","author":"O Ganry","year":"2004","unstructured":"Ganry O, Peng J, Dubreuil A (2004) Influence of abnormal screens on delays and prognostic indicators of screen-detected breast carcinoma. J Med Screen 11(1):28\u201331","journal-title":"J Med Screen"},{"key":"7219_CR28","unstructured":"Danckert BFJ, Engholm G , Hansen HL, Johannesen TB, Khan S, K\u00f8tlum JE, \u00d3lafsd\u00f3ttir E, Schmidt LKH, Virtanen A and Storm HH (2019) NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, Version 8.2 (26.03.2019) [homepage on the internet]. Association of the Nordic Cancer Registries. Danish Cancer Society. Available from: http:\/\/www.ancr.nu"},{"key":"7219_CR29","unstructured":"Ferlay J EM, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2020) Global cancer observatory: cancer today [homepage on the internet]. International Agency for Research on Cancer, Lyon, France [Available from: https:\/\/gco.iarc.fr\/today"},{"issue":"1","key":"7219_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-006-9425-3","volume":"105","author":"S Ciatto","year":"2007","unstructured":"Ciatto S, Houssami N, Ambrogetti D, Bonardi R, Collini G, Del Turco MR (2007) Minority report\u2014false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis. Breast Cancer Res Treat 105(1):37\u201343","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7219_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.canep.2014.06.006","volume":"38","author":"M von Euler-Chelpin","year":"2014","unstructured":"von Euler-Chelpin M, Kuchiki M, Vejborg I (2014) Increased risk of breast cancer in women with false-positive test: the role of misclassification. Cancer Epidemiol 38(5):619\u2013622","journal-title":"Cancer Epidemiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07219-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07219-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T13:18:53Z","timestamp":1714569533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07219-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["7219"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07219-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial and non-financial interests: Dr Xavier Castells, and Dr Marta Rom\u00e1n participated in iCAD, Inc. PROFOUND AI RISK Trial and their institution received money from iCAD outside the submitted work. All other authors declare no financial or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Danish data: According to the Consolidation Act on Research Ethics Review of Health Research Projects, Consolidation Act number 1083 of 15 September 2017 section\u00a014 (2) notification of questionnaire surveys or medical database research projects to the research ethics committee system is only required if the project involves human biological material. Therefore, this study may be conducted without an approval from the committees. Spanish data: In Spain, no ethics committee approval was required, since completely anonymized and aggregated data were provided for the study. The requirement to obtain informed consent was waived. Norwegian data: This study has legal basis in accordance with Articles 6 (1) (e) and 9 (2) (j) of the GDPR. The data were disclosed with legal basis in the Cancer Registry Regulations section\u00a03\u20131 () and the Personal Health Data Filing System Act section\u00a019 a to 19 h ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}